Investing.com - Y mAbs Therapeutics (NASDAQ: YMAB) reported first quarter EPS of $-0.15, worse than the analyst estimate of $-0.14. Revenue for the quarter came in at $19.93M versus the consensus estimate of $22.84M.
Guidance
Y mAbs Therapeutics sees FY 2024 revenue of $95.00M-$100.00M versus the analyst consensus of $96.87M.
Y mAbs Therapeutics's stock price closed at $17.21. It is up 31.27% in the last 3 months and up 154.21% in the last 12 months.
Y mAbs Therapeutics saw 1 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Y mAbs Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Y mAbs Therapeutics's Financial Health score is "great performance".
Check out Y mAbs Therapeutics's recent earnings performance, and Y mAbs Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar